These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7651743)

  • 21. The c-Abl tyrosine kinase stabilizes Pitx1 in the apoptotic response to DNA damage.
    Yamaguchi T; Miki Y; Yoshida K
    Apoptosis; 2010 Aug; 15(8):927-35. PubMed ID: 20563669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P130 and its truncated form mediate p53-induced cell cycle arrest in Rb(-/-) Saos2 cells.
    Gao CF; Ren S; Wang J; Zhang SL; Jin F; Nakajima T; Ikeda M; Tsuchida N
    Oncogene; 2002 Oct; 21(49):7569-79. PubMed ID: 12386819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p120-v-Abl expression overcomes TGF-beta1 negative regulation of c-myc transcription but not cell growth.
    Birchenall-Roberts MC; Kim SJ; Bertolette DC; Turley JM; Fu T; Bang OS; Kasper JJ; Yoo YD; Ruscetti FW
    Oncogene; 1996 Oct; 13(7):1499-509. PubMed ID: 8875988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle.
    Welch PJ; Wang JY
    Cell; 1993 Nov; 75(4):779-90. PubMed ID: 8242749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
    Wen ST; Jackson PK; Van Etten RA
    EMBO J; 1996 Apr; 15(7):1583-95. PubMed ID: 8612582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.
    Whang YE; Tran C; Henderson C; Syljuasen RG; Rozengurt N; McBride WH; Sawyers CL
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5486-91. PubMed ID: 10805805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nuclear tyrosine kinase c-Abl negatively regulates cell growth.
    Sawyers CL; McLaughlin J; Goga A; Havlik M; Witte O
    Cell; 1994 Apr; 77(1):121-31. PubMed ID: 7512450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.
    Shaulsky G; Ben-Ze'ev A; Rotter V
    Oncogene; 1990 Nov; 5(11):1707-11. PubMed ID: 2267137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms.
    Haupt Y; Rowan S; Shaulian E; Kazaz A; Vousden K; Oren M
    Leukemia; 1997 Apr; 11 Suppl 3():337-9. PubMed ID: 9209383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73.
    Wang JY; Ki SW
    Biochem Soc Trans; 2001 Nov; 29(Pt 6):666-73. PubMed ID: 11709051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA damage stress response in germ cells: role of c-Abl and clinical implications.
    Gonfloni S
    Oncogene; 2010 Nov; 29(47):6193-202. PubMed ID: 20818431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-Abl neutralizes the inhibitory effect of Mdm2 on p53.
    Sionov RV; Moallem E; Berger M; Kazaz A; Gerlitz O; Ben-Neriah Y; Oren M; Haupt Y
    J Biol Chem; 1999 Mar; 274(13):8371-4. PubMed ID: 10085066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis.
    Shinohara H; Zhou J; Yoshikawa K; Yazumi S; Ko K; Yamaoka Y; Mizukami T; Yoshida T; Akinaga S; Tamaoki T; Motoda H; Benedict WF; Takahashi R
    Br J Cancer; 2000 Oct; 83(8):1039-46. PubMed ID: 10993652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of cell death by the Abl tyrosine kinase.
    Wang JY
    Oncogene; 2000 Nov; 19(49):5643-50. PubMed ID: 11114745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization.
    Nie Y; Li HH; Bula CM; Liu X
    Mol Cell Biol; 2000 Feb; 20(3):741-8. PubMed ID: 10629029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53.
    Yuan ZM; Huang Y; Fan MM; Sawyers C; Kharbanda S; Kufe D
    J Biol Chem; 1996 Oct; 271(43):26457-60. PubMed ID: 8900110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI, a protein that binds the enhancers of several viruses and cell-cycle regulated genes.
    Agami R; Shaul Y
    Oncogene; 1998 Apr; 16(14):1779-88. PubMed ID: 9583676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of differentially phosphorylated Rb and mutant p53 proteins in myeloid leukemia cell lines.
    Sen S; Takahashi R; Rani S; Freireich EJ; Stass SA
    Leuk Res; 1993 Aug; 17(8):639-47. PubMed ID: 8355507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress.
    Lee JH; Jeong MW; Kim W; Choi YH; Kim KT
    J Biol Chem; 2008 Jul; 283(28):19826-35. PubMed ID: 18490454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insights into selective activation of p53 DNA binding by c-Abl.
    Wei G; Li AG; Liu X
    J Biol Chem; 2005 Apr; 280(13):12271-8. PubMed ID: 15661746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.